Research·October 24, 2026 at 12:00 PM EDT·1 source
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
AZN -0.6%LLY
AZN · last 30 trading days-0.6% since the news
News
What happened
- ESMO26 is drawing an estimated almost 40,000 delegates to Madrid over five days.
- Saturday’s new data include presentations from AstraZeneca, Eli Lilly and Bayer.
- The article highlights oncology competition involving Keytruda, Padcev, Elahere and Nubeqa.
Estimated ESMO26 delegates
almost 40,000
Congress duration
five days
Why it matters
The data may inform oncology professionals’ views of competitive positioning and treatment development across several cancer indications.
What to watch. New data presentations from AstraZeneca, Eli Lilly and Bayer at ESMO26.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 19Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
- EarlierOct 22Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
- EarlierOct 23China’s rapid human trials draw western drugmakers — and safety concerns
- EarlierYesterdayAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- First reported by Endpoints NewsYesterday#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
Who is involved
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC…AstraZenecaAZNEli LillyLLYBayerKeytrudaPadcevElahereNubeqa
Company
Sources (1)
Related
- 3h · STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase
- 5h · #ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
- Yesterday · Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Oct 19 · Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
- Oct 23 · China’s rapid human trials draw western drugmakers — and safety concerns
- Oct 22 · Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.